SIH Partners’s Axsome Therapeutics AXSM Stock Holding History

SIH Partners’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,071	Closed	-$358K	–	180
2025 Q1	$358K	Buy	+3,071	New	+$350K	0.01%	181

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

SIH Partners's AXSM Position: Q2 2025 in Review

SIH Partners sold out of Axsome Therapeutics (AXSM) in Q2 2025, closing a stake of 3,071 shares — an estimated $358K sold.

SIH Partners first reported a position in AXSM in Q1 2025 and held it in 1 quarter. The position peaked at $358K in Q1 2025. 348 funds tracked by Wall St. Rank hold AXSM as of Q2 2025.

SIH Partners reported no remaining Axsome Therapeutics position as of Q2 2025 after selling out during the quarter.
SIH Partners sold 3,071 Axsome Therapeutics shares in Q2 2025, an estimated $358K.
SIH Partners first reported a position in Axsome Therapeutics in Q1 2025 and held it in 1 quarter.
SIH Partners's Axsome Therapeutics position peaked at $358K in Q1 2025.
348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2025.

Based on SIH Partners's 13F filing for Q2 2025, filed 14 Aug 2025.